08:35 AM EDT, 06/26/2025 (MT Newswires) -- Cellectar Biosciences ( CLRB ) said Thursday it signed a multi-year agreement with physics firm Nusano for the supply of iodine-125 and actinium-225 for clinical studies and future commercial needs.

The isotopes will provide the necessary clinical development supply for the company's clinical-stage programs, including CLR 125 for triple-negative breast cancer and CLR 225 for pancreatic cancer, Cellectar CEO James Caruso said.